Possible influence of variant of the P-glycoprotein gene (MDR1/ABCB1) on clinical response to guanfacine in children with pervasive developmental disorders and hyperactivity

Journal of Child and Adolescent Psychopharmacology

Volumn 20, Issue 1, 2010, Pages 1-5

  McCracken, James T ^a   Aman, Michael G ^a   McDougle, Christopher J ^a   Tierney, Elaine ^a   Shiraga, Sharon ^a   Whelan, Fiona ^a   Arnold, L Eugene ^a   Posey, David ^a   Ritz, Louise ^a   Vitiello, Benedetto ^a   Scahill, Lawrence ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUANFACINE; MULTIDRUG RESISTANCE PROTEIN 1;

ARTICLE; AUTISM; BEDTIME DOSAGE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DISRUPTIVE BEHAVIOR; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPERACTIVITY; MALE; OUTCOME ASSESSMENT; SCHOOL CHILD; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ADOLESCENT; ADRENERGIC ALPHA-AGONISTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; FEMALE; GENETIC VARIATION; GENOTYPE; GUANFACINE; HUMANS; MALE; P-GLYCOPROTEIN; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 77249163833     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2009.0059     Document Type: Article

References (27)

1. Aman MG, Singh NN, Stewart AW, Field CJ: The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects. Am J Ment Deficiency 89:485-491, 1985.
2. Aman MG, Buican B, Arnold LE: Methylphenidate treatment in children with borderline IQ and mental retardation: Analysis of three aggregated studies. J Child Adoles Psychopharmacol 13:27-38, 2003.
3. th edition (DSM-IV). Washington (DC): American Psychiatric Association, 1994.
4. Biederman J, Melmed RD, Patel A, McBurnett K, Konow J, Lyne A, Scherer N, SPD503 Study Group: A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit=hyperactivity disorder. Pediatrics 121:e73-e84, 2008a.
5. Biederman J, Melmed RD, Patel A, McBurnett K, Donahue J, Lyne A: Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. CNS Spectr 13:1047-1055, 2008b.
6. Brown EC, Aman MG, Havercamp SM: Factor analysis and norms for parent ratings on the Aberrant Behavior Checklist - Community for young people in special education. Res Develop Disabil 23:45-60, 2002.
7. Cummings DD, Singer HS, Krieger M, Miller TL, Mahone EM: Neuropsychiatric effects of guanfacine in children with mild Tourette syndrome: A pilot study. Clin Neuropharmacol 25:325-332, 2002.
8. Daviss WB, Patel NC, Robb AS, McDermott MP, Bukstein OG, Pelham WE, Palumbo D, Harris P, Sallee FR, The CAT STUDY TEAM: Clonidine for attention-deficit=hyperactivity disorder: ECG changes and adverse events analysis. J Am Acad Child Adolesc Psychiatry 47:2:189-198, 2008.
9. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U: Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473-3478, 2000.
10. Jaselskis CA, Cook EH Jr, Fletcher KE, Leventhal BL: Clonidine treatment of hyperactive and impulsive children with autism. J Clin Psychopharmacol 12:322-327, 1992.
11. Kimchi-Sarfaty C, Oh JM, Kim I-W, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM: A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315:525-528, 2007.
12. Lecavalier L: Behavior and emotional problems in young people with pervasive developmental disorders: Relative prevalence, effects of subject characteristics, and empirical classification. J Autism Develop Disord 36:1101-1114, 2006.
13. Lord C, Pickles A, McLennan J, Rutter, M, Bregman J, Folstein S, Fombonne E, Leboyer M, Minshew N: Diagnosing autism: Analyses of data from the Autism Diagnostic Interview. J Autism Develop Disord 27:501-517, 1997.
14. Maeda K, Sugiyama Y: Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic, and toxicological properties of anionic drugs. Drug Metab Pharmacokinet 23: 223-235, 2008.
15. Marshburn EC, Aman MG: Factor validity and norms for the Aberrant Behavior Checklist in a community sample of children with mental retardation. J Autism Develop Disord 22:357-373, 1992.
16. Marzolini C, Paus E, Buclin T, Kim RB: Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance. Clin Pharmacol Ther 75:13-33, 2004.
17. Newcorn JH, Schulz KP, Halperin JM: Adrenergic agonists: Clonidine and guanfacine. In Martin A, Scahill L, Charney DS, Leckman JF (eds). Pediatric Psychopharmacology: Principles and Practice. New York: Oxford, pp 264-273, 2003.
18. Posey DJ, Puntney JI, Sasher TM, Kem DL, McDougle CJ: Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: A retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol 14:233-241, 2004.
19. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network: Methylphenidate in children with PDD and hyperactivity. Arch Gen Psychiatry 62:1266-1274, 2005.
20. Rush AJ, Francis A: Expert Consensus Guideline Series: Treatment of psychiatric and behavioral problems in mental retardation. (Special issue.) Am J Mental Retardat 105:159-228, 2000.
21. Sakaeda T: MDR1 genotype-related pharmacokinetics: Fact or fiction? Drug Metab Pharmacokinet 20:391-414, 2005.
22. Scahill L, Chappell PB, Kim YS, Schultz RT, Katsovich L, Shepherd E, Arnsten AFT, Cohen DJ, Leckman JF: Guanfacine in the treatment of children with tic disorders and ADHD: A placebocontrolled study. Am J Psychiatry 158:1067-1074, 2001.
23. Scahill L, Aman MG, McDougle CJ, McCracken JT, Tierney E, Dziura J, Arnold LE, Posey D, Young C, Shah B, Ghuman J, Ritz L, Vitiello B: A prospective open trial of guanfacine in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol 16:589-598, 2006.
24. Schinkel AH, Jonker JW: Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: An overview. Adv Drug Deliv Rev 21;55:3-29, 2003.
25. Swanson JM, Kraemer HC, Hinshaw SP, Arnold LE, Conners CK, Abikoff HB, Clevenger W, Davies M, Elliott G, Greenhill LL, Hechtman L, Hoza B, Jensen PS, March JS, Newcorn JH, Owens L, Pelham WE, Schiller E, Severe J, Simpson S, Vitiello B, Wells CK, Wigal T, Wu M: Clinical relevance of the primary findings of theMTA: Success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry 40:168-179, 2001.
26. The MTA Cooperative Group: A 14-Month randomized clinical trial of treatment strategies for attention-deficit=hyperactivity disorder. Arch Gen Psychiatry 56:1073-1086, 1999.
27. Wang JS, Newport DJ, Stowe ZN, Donovan JL, Pennell PB, DeVane CL: The emerging importance of transporter proteins in the psychopharmacological treatment of the pregnant patient. Drug Metab Rev 39:723-746, 2007.